Figure 2.

Detection of rPrP^Sc in brain tissues obtained at biopsy and autopsy. A: rPrP^Sc in brain tissue obtained at biopsy was detected with Western blot analysis. Ten percent of brain homogenates from the current case, negative (Neg), or positive (Pos) CJD cases were treated with or without PK. A 5 μl or 20 μl of sample each was used for Western blotting. PK-resistant PrP was detected in either 5 μl or 20 μl of samples of the current case. The gel mobility of the PK-resistant PrP fragments from this case matches that of rPrP^Sc type 1 control. T1, rPrP^Sc type 1 control; T2, rPrP^Sc type 2 control. B: The rPrP^Sc in brain sample obtained at autopsy was also examined with Western blotting. Blots in A and B were probed with 3F4.